ERBB2 and non-small cell lung carcinoma: In addition, the propensity of HER2-mutant NSCLC for central nervous system (CNS) involvement during the course of treatment will require tailor-made algorithms for the early identification of CNS metastases as well as careful assessment of the intracranial activity of the existing and upcoming anti-HER2 agents.